Cutera, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Taylor C. Harris
- Full Time Employees
- 430
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 3240 Bayshore Boulevard Brisbane CA United States of America 94005
- IPO Date
- Mar 31, 2004
- CIK
- 0001162461
- Website
- cutera.com
- Similar Companies
- Business
- Cutera, Inc. is a global medical device company specializing in the design, development, manufacturing, and marketing of laser and energy-based aesthetic systems for the practitioner-attended aesthetic market. Its core product portfolio includes solutions for aesthetic and dermatologic applications such as hair removal; acne, wrinkle, and scar treatment; skin resurfacing; body contouring; vascular and pigmented lesion treatment; and tattoo removal. Key product brands include the TruSculpt body sculpting systems, the excel V+ and excel HR vascular and hair removal platforms, and the Solera and enlighten laser platforms. Founded in 1998 and headquartered in Brisbane, California, Cutera serves medical professionals including dermatologists, plastic surgeons, and specialty clinics primarily across the Americas, Europe, and Asia-Pacific regions. The company is focused on innovative technology development to expand its treatment offerings for both aesthetic and medical dermatology practitioners. In the last two years, Cutera has advanced its strategic position through new product launches such as next-generation TruSculpt platforms and enhancements to its vascular treatment systems. It has also established partnerships aimed at broadening clinical applications and expanding geographic reach. Cutera continues investing in research and development to maintain a competitive edge in laser and energy-based treatments, reflecting a commitment to pioneering non-invasive aesthetic solutions globally. There have been no recent name changes or major restructurings reported through 2025. The company operates primarily in the aesthetic medical devices industry, targeting practitioner-based customer segments worldwide. It leverages a direct sales organization alongside distributors to market its products in over 70 countries, emphasizing innovation in non-invasive technologies and clinical efficacy to meet evolving market demands. Cutera remains independently publicly traded under the ticker symbol CUTR.
Cutera® Appoints Chris House as Chief Technology Officer and Charles Hunt as Vice President of Design & Experience, Reinforcing Commitment to Innovation
Cutera® Successfully Completes Restructuring Transaction and Moves Forward with Enhanced Capital Structure
Cutera Announces Voluntarily Delisting from Nasdaq
Cutera Takes Steps to Strengthen Financial Foundation and Position the Company for Long-Term Success
Dermatology Devices Market Report 2025, with Key Player Profiles for Cutera, Lumenis, Alma Lasers, Solta Medical and Aesthetic Group
Aesthetic Medicine Market Expected To Reach USD 170.41 Billion by 2032, Growing at CAGR 8.40% | Allergan, Alma Lasers, Cutera, Cynosure
Cutera® Announces Partnership with the Adaptive Training Foundation
Cutera, Inc. (CUTR) Q3 2024 Earnings Call Transcript
Cutera (CUTR) Reports Q3 Loss, Misses Revenue Estimates
Cutera® to Announce Third Quarter Results on November 7, 2024
Cutera (CUTR) Stock Drops 5.14% Amid Financial Challenges
Cutera, Inc (CUTR) Q2 2024 Earnings Call Transcript
Cutera (CUTR) Reports Q2 Loss, Misses Revenue Estimates
Investor Alert: 3 Ugly Celebrity Beauty Brand Stocks Not Worth Your Dollar
Cutera® Announces New Survey Data During Acne Awareness Month
Cutera® Appoints Jeryl L. Hilleman to Board of Directors
The 3 Most Undervalued Meme Stocks to Buy in June 2024
Cutera® Announces AviClear® Investor Webinar
If You Can Only Buy One Meme Stock Now, It Better Be One of These 3 Names
Trade of the Day: Cutera (CUTR) Stock Presents a Short Squeeze Opportunity